Hepatitis A Infection (Acute Hepatitis)
Overview
Plain-Language Overview
Hepatitis A Infection (Acute Hepatitis) is a contagious liver disease caused by the Hepatitis A virus. It primarily affects the liver, an organ responsible for filtering toxins and producing important proteins. The infection leads to inflammation of the liver, which can cause symptoms like fatigue, jaundice (yellowing of the skin and eyes), and abdominal discomfort. It spreads mainly through ingestion of contaminated food or water. Most people recover fully without long-term liver damage, but the illness can temporarily disrupt normal liver function. The disease is more common in areas with poor sanitation and can affect people of all ages.
Clinical Definition
Hepatitis A Infection (Acute Hepatitis) is an acute inflammatory condition of the liver caused by the Hepatitis A virus (HAV), a non-enveloped RNA virus transmitted via the fecal-oral route. The virus infects hepatocytes, leading to immune-mediated hepatocellular injury rather than direct cytopathic effects. The infection typically results in a self-limited illness characterized by acute hepatitis with symptoms such as jaundice, elevated aminotransferases, and systemic signs like fever and malaise. Unlike other viral hepatitis forms, it does not cause chronic infection or carrier state. The disease is significant due to its high infectivity and potential to cause outbreaks, especially in settings with inadequate sanitation. Diagnosis and management focus on supportive care, as there is no specific antiviral treatment.
Inciting Event
Ingestion of HAV-contaminated food or water initiates infection.
Close personal contact with an infected person during the infectious period.
Outbreaks linked to contaminated shellfish or produce are common inciting events.
Latency Period
Incubation period ranges from 15 to 50 days, typically around 28 days before symptom onset.
Viral shedding in stool begins approximately 2 weeks before symptoms appear.
Diagnostic Delay
Nonspecific prodromal symptoms such as malaise and anorexia can mimic other viral illnesses.
Lack of jaundice in children may delay clinical suspicion of hepatitis.
Misattribution to other causes of acute hepatitis such as drug-induced liver injury or other viral hepatitis types.
Limited access to serologic testing in resource-poor settings delays diagnosis.
Clinical Presentation
Signs & Symptoms
Fatigue and malaise are common early symptoms
Anorexia, nausea, and vomiting frequently precede jaundice
Dark urine and pale stools due to cholestasis
Right upper quadrant abdominal pain and discomfort
Low-grade fever and arthralgia may be present
History of Present Illness
Prodromal phase with fatigue, anorexia, nausea, and low-grade fever lasting several days.
Development of jaundice, dark urine, and pale stools indicating cholestasis and hepatocellular injury.
Right upper quadrant abdominal discomfort due to liver inflammation.
Symptoms typically resolve within 2 months without progression to chronic disease.
Past Medical History
Lack of prior HAV vaccination increases susceptibility.
Previous exposure to contaminated food or water may be relevant.
No history of chronic liver disease as HAV does not cause chronic infection.
Family History
No significant heritable predisposition to HAV infection.
Family members may have similar exposure risks during outbreaks.
No known familial syndromes associated with HAV infection.
Physical Exam Findings
Jaundice with yellowing of the sclera and skin due to elevated bilirubin
Hepatomegaly with a tender, enlarged liver on palpation
Right upper quadrant tenderness on abdominal exam
Icteric sclera indicating hyperbilirubinemia
Mild fever and signs of systemic inflammation
Diagnostic Workup
Diagnostic Criteria
Diagnosis of hepatitis A infection is established by detecting anti-HAV IgM antibodies in the serum, which indicate recent acute infection. Elevated serum aminotransferases (AST and ALT) typically exceed 1000 IU/L during the acute phase. Clinical presentation with jaundice, dark urine, and elevated bilirubin supports the diagnosis. Molecular tests such as HAV RNA PCR can confirm infection but are less commonly used. Serologic testing remains the gold standard for confirming acute hepatitis A.
Pathophysiology
Key Mechanisms
Fecal-oral transmission of Hepatitis A virus leads to infection of hepatocytes.
Immune-mediated hepatocyte injury occurs as cytotoxic T cells target infected liver cells.
Viral replication in hepatocytes causes cellular dysfunction and inflammation.
Cholestasis results from hepatocellular injury impairing bile flow.
Robust humoral immune response with production of anti-HAV IgM and IgG antibodies facilitates viral clearance.
| Involvement | Details |
|---|---|
| Organs | Liver is the primary organ involved, where hepatitis A virus replicates and causes acute inflammation leading to clinical hepatitis. |
Gallbladder may be involved secondarily with transient cholestasis and mild inflammation during acute infection. | |
| Tissues | Liver parenchyma is the main tissue affected, showing inflammation, hepatocyte necrosis, and regeneration during acute hepatitis A. |
| Cells | Hepatocytes are the primary target cells infected by hepatitis A virus, leading to liver inflammation and injury. |
Kupffer cells act as liver-resident macrophages that mediate immune response and clearance of infected cells. | |
CD8+ cytotoxic T cells contribute to hepatocyte injury by targeting virus-infected cells during the immune response. | |
| Chemical Mediators | Interferon-gamma is produced by activated T cells and plays a key role in antiviral defense and inflammation. |
Tumor necrosis factor-alpha (TNF-α) mediates hepatocyte apoptosis and promotes inflammatory liver damage. | |
Alanine aminotransferase (ALT) is a biochemical marker elevated in serum indicating hepatocellular injury. |
Treatments
Pharmacological Treatments
Non-pharmacological Treatments
Supportive care with hydration and rest is essential to manage symptoms of acute hepatitis A infection.
Avoidance of alcohol and hepatotoxic drugs to prevent further liver injury is recommended.
Nutritional support with a balanced diet helps maintain liver function during recovery.
Prevention
Pharmacological Prevention
Inactivated hepatitis A vaccine provides effective active immunization
Immune globulin (IG) for post-exposure prophylaxis within 2 weeks
Vaccination recommended for travelers to endemic areas and high-risk groups
No antiviral therapy available for acute hepatitis A
Booster doses of vaccine may be required for long-term immunity
Non-pharmacological Prevention
Hand hygiene with soap and water to prevent fecal-oral transmission
Safe drinking water and proper sanitation reduce infection risk
Avoidance of contaminated food especially shellfish and raw produce
Public health measures including outbreak control and education
Screening and vaccination of high-risk populations such as healthcare workers
Outcome & Complications
Complications
Fulminant hepatic failure is a rare but life-threatening complication
Cholestatic hepatitis causing prolonged jaundice and pruritus
Relapsing hepatitis with recurrent symptoms weeks after initial recovery
Acute kidney injury secondary to severe liver dysfunction
Autoimmune hepatitis triggered by viral infection in predisposed individuals
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
Hepatitis A Infection (Acute Hepatitis) versus Hepatitis B Infection
Hepatitis A Infection (Acute Hepatitis) | Hepatitis B Infection |
|---|---|
Fecal-oral transmission via contaminated food or water | Parenteral exposure, sexual contact, or vertical transmission |
Positive anti-HAV IgM antibody | Positive hepatitis B surface antigen (HBsAg) and hepatitis B core antibody IgM |
Self-limited acute illness without chronic infection | Potential progression to chronic hepatitis and hepatocellular carcinoma |
Hepatitis A Infection (Acute Hepatitis) versus Hepatitis C Infection
Hepatitis A Infection (Acute Hepatitis) | Hepatitis C Infection |
|---|---|
Fecal-oral transmission, often from contaminated water | History of intravenous drug use or blood transfusion |
Positive anti-HAV IgM antibody | Positive HCV RNA PCR and anti-HCV antibodies |
Symptomatic acute illness with spontaneous resolution | Often asymptomatic acute phase with high risk of chronic infection |
Hepatitis A Infection (Acute Hepatitis) versus Alcoholic Hepatitis
Hepatitis A Infection (Acute Hepatitis) | Alcoholic Hepatitis |
|---|---|
No history of alcohol abuse, recent exposure to HAV | Chronic heavy alcohol use |
Elevated ALT > AST with marked increase in bilirubin | Elevated AST > ALT with AST:ALT ratio > 2 |
Acute self-limited hepatitis without chronic liver damage | Chronic progressive liver injury with possible cirrhosis |
Hepatitis A Infection (Acute Hepatitis) versus Autoimmune Hepatitis
Hepatitis A Infection (Acute Hepatitis) | Autoimmune Hepatitis |
|---|---|
Absence of autoimmune antibodies, positive anti-HAV IgM | Presence of antinuclear antibodies (ANA) and anti-smooth muscle antibodies |
No characteristic autoimmune histology, viral serology positive | Liver biopsy showing interface hepatitis with plasma cell infiltrate |
Supportive care only, no immunosuppressive therapy needed | Improvement with corticosteroids and immunosuppressants |
Hepatitis A Infection (Acute Hepatitis) versus Wilson Disease
Hepatitis A Infection (Acute Hepatitis) | Wilson Disease |
|---|---|
More common in children and young adults but can occur at any age | Typically presents in adolescents or young adults |
Normal ceruloplasmin, positive anti-HAV IgM | Low serum ceruloplasmin and elevated 24-hour urinary copper |
Acute hepatocellular injury without copper accumulation | Hepatic copper accumulation with chronic liver damage |